As dual-payload and novel-payload ADCs fuel the next wave of innovation in the ADC space, the spotlight is shifting to the chemistry behind these advancements. With the need for strategies to overcome payload hydrophobicity, achieve optimal stability profiles, and reduce aggregation, linker and conjugation strategies have become crucial levers for unlocking improved therapeutic windows. Returning to Boston this August, the 3rd ADC Linker and Conjugation Summit is the only meeting fully dedicated to the chemistry that underpins ADC success. Join 80+ experts from AstraZeneca, Pfizer, Sutro Biopharma, Glykos, Catena Biosciences, Tubulis, and more for three days of focused insights and technical exchange.